secwatch.observer — SEC 8-K summary
======================================

Issuer:     GLOBUS MEDICAL INC (GMED)
CIK:        0001237831
Form:       8-K
Filed at:   2022-04-21T23:59:59+00:00
Accession:  0001562762-22-000187
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Globus Medical names Dan Scavilla as CEO replacing Demski; prelim Q1 sales $230.5M +1.4% YoY
--------------------------------------------------------------------------------

- David Demski resigned as CEO effective April 21, 2022; not due to any disagreement; will assist transition through June 30.
- Daniel T. Scavilla appointed President & CEO; previously EVP Chief Commercial Officer and President of Trauma.
- Preliminary Q1 2022 sales approx. $230.5M, up 1.4% vs Q1 2021; full-year 2022 guidance reaffirmed: $1.025B sales, non-GAAP EPS $2.10.
- Scavilla's base salary increased to $450K; target annual non-equity incentive to $900K; receives option for 60,000 shares vesting 4 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1237831/000156276222000187/0001562762-22-000187-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1237831/000156276222000187/gmed-20220421x8k.htm
  HTML page:      https://secwatch.observer/filing/0001562762-22-000187

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer